| BOC Sciences | USA | Inquire | ||
|---|---|---|---|---|
![]() |
+1 (631) 485-4226 | |||
![]() |
info@bocsci.com | |||
| Chemical manufacturer | ||||
| chemBlink standard supplier since 2010 | ||||
| Chengdu Youngshe Chemical Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (28) 6232-8193 +86 17380623303 | |||
![]() |
caroline@youngshechem.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2013 | ||||
| chemBlink standard supplier since 2015 | ||||
| Chengdu Jinglin Biotechnology Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 17380623303 | |||
![]() |
yunxicaroline@gmail.com | |||
![]() |
QQ chat | |||
| Chemical distributor since 2021 | ||||
| chemBlink standard supplier since 2022 | ||||
| Cn Chemunion Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 17366116869 | |||
![]() |
david@cnchemunion.com | |||
![]() |
QQ chat | |||
![]() |
WeChat: +86 15250069576 | |||
![]() |
WhatsApp: +86 17366116869 | |||
| Chemical manufacturer since 2019 | ||||
| chemBlink standard supplier since 2024 | ||||
| Guangzhou Congen Pharmatec Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 13380081396 | |||
![]() |
marketing@congenpharm.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
![]() |
WeChat: Shine_Huang2014 | |||
![]() |
WhatsApp: +8613242332900 | |||
| Chemical manufacturer since 2013 | ||||
| chemBlink standard supplier since 2025 | ||||
| Guangzhou Amsper Biotechnology Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+8618565278009 | |||
![]() |
gifty@amsper.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
![]() |
WeChat: +8618565278009 | |||
![]() |
WhatsApp: +8618565278009 | |||
| Chemical distributor since 2018 | ||||
| chemBlink standard supplier since 2025 | ||||
| Classification | API >> Antibiotics >> Peptide drug |
|---|---|
| Name | mu-Conotoxin Cn IIIC |
| Synonyms | 5-Oxo-L-prolylglycyl-L-cysteinyl-L-cysteinyl-L-asparaginylglycyl-L-prolyl-L-lysylglycyl-L-cysteinyl-L-seryl-L-seryl-L-lysyl-L-tryptophyl-L-cysteinyl-L-arginyl-L-alpha-aspartyl-L-histidyl-L-alanyl-L-arginyl-L-cysteinyl-L-cysteinamide cyclic (3→15),(4→21),(10→22)-tris(disulfide); 2-[(1R,4S,7S,10S,13S,16R,19S,22S,25S,28S,31S,34R,39R,42S,51S,54S,64R,69R)-10,54-bis(4-aminobutyl)-42-(2-amino-2-oxoethyl)-19,31-bis(3-carbamimidamidopropyl)-64-carbamoyl-4,7-bis(hydroxymethyl)-25-(1H-imidazol-5-ylmethyl)-13-(1H-indol-3-ylmethyl)-28-methyl-2,5,8,11,14,17,20,23,26,29,32,40,43,46,52,55,58,66,68-nonadecaoxo-69-[[2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]acetyl]amino]-36,37,61,62,71,72-hexathia-3,6,9,12,15,18,21,24,27,30,33,41,44,47,53,56,59,65,67-nonadecazatetracyclo[32.25.7.716,39.047,51]triheptacontan-22-yl]acetic acid |
| Molecular Structure | ![]() |
| Protein Sequence | XGCCNGPKGCSSKWCRDHARCC |
| Molecular Formula | C92H139N35O28S6 |
| Molecular Weight | 2375.70 |
| CAS Registry Number | 936616-33-0 |
| EC Number | 692-855-7 |
| SMILES | C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@H](NC2=O)C(=O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)NC(=O)CNC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC6=CN=CN6)CC(=O)O)CCCNC(=N)N)CC7=CNC8=CC=CC=C87)CCCCN)CO)CO)CCCCN)CC(=O)N)CCCNC(=N)N |
| Density | 1.71±0.1 g/cm3 (20 ºC 760 Torr), Calc.* |
|---|---|
| * | Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (©1994-2019 ACD/Labs) |
| Hazard Symbols |
| ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Statements | H301+H311+H331-H301-H311-H331 Details | ||||||||||||||||||||
| Precautionary Statements | P261-P262-P264-P270-P271-P280-P301+P316-P302+P352-P304+P340-P316-P321-P330-P361+P364-P403+P233-P405-P501 Details | ||||||||||||||||||||
| Hazard Classification | |||||||||||||||||||||
| |||||||||||||||||||||
|
mu-Conotoxin Cn IIIC was discovered as part of ongoing research into the venom of marine cone snails, specifically Conus consors, in the early 21st century. This peptide toxin is part of a broader group of conotoxins known for their ability to selectively target ion channels and receptors in the nervous system. Researchers isolated mu-Conotoxin Cn IIIC due to its potent effects on sodium channels, making it a valuable tool for studying nerve function and potential therapeutic applications. One of the primary applications of mu-Conotoxin Cn IIIC is in neuroscientific research. By selectively blocking specific sodium channels, it allows researchers to study the roles of these channels in nerve signal transmission and pain pathways. This specificity helps in understanding the fundamental mechanisms of nerve function and disorders. Due to its ability to block sodium channels involved in pain transmission, mu-Conotoxin Cn IIIC has potential as a novel pain management therapy. Its specificity for certain sodium channels could provide pain relief without the side effects associated with traditional analgesics like opioids. Sodium channels play a crucial role in cardiac function. mu-Conotoxin Cn IIIC can be used to study these channels' roles in heart muscle contraction and arrhythmias. By providing insights into the molecular mechanisms of heart function and dysfunction, it can contribute to the development of new treatments for heart disease. The high specificity and potency of mu-Conotoxin Cn IIIC make it a valuable tool in biotechnology. It can be used in the development of diagnostic assays for sodium channel function and in the screening of new drugs targeting these channels. Ongoing research aims to modify and optimize mu-Conotoxin Cn IIIC for therapeutic use. Its potential in treating neurological disorders, such as epilepsy and multiple sclerosis, is being explored. |
| Market Analysis Reports |
| List of Reports Available for mu-Conotoxin Cn IIIC |